1
|
Riaz U, Rakesh L, Shabib I, Haider W. Effect of dissolution of magnesium alloy AZ31 on the rheological properties of Phosphate Buffer Saline. J Mech Behav Biomed Mater 2018; 85:201-208. [PMID: 29908488 DOI: 10.1016/j.jmbbm.2018.06.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2018] [Revised: 04/19/2018] [Accepted: 06/01/2018] [Indexed: 01/29/2023]
Abstract
The issue of long-term incompatible interactions associated with the permanent implants can be eliminated by using various biodegradable metal implants. The recent research is focusing on the use of degradable stents to restore most of the hindrances of capillaries, and coronary arteries by supplying instant blood flow with constant mechanical and structural support. However, internal endothelialization and infection due to the corrosion of implanted stents are not easy to diagnose in the long run. In the recent past, magnesium (Mg) has been widely investigated for the cardiovascular stent applications. Here we made an attempt to understand the biodegradation process of Mg alloy stent by studying the degradation of Mg alloy AZ31 (3 wt% Aluminum, 1 wt% Zn) powder at various time-intervals in simulated blood fluid using the Rheological methods. The degradability of the Mg stent in the arteries affects the stress-strain properties of blood plasma and the subsequent flow conditions. Blood and plasma viscosities alter due to the degradation of Mg resulting from the stress-strain experienced in the blood vessels, in which the stent is inserted. Here our objective was to explore the influence of Mg degradation on the blood plasma viscosity by studying the viscoelastic properties. In this work, the effect of dissolution of Mg alloy AZ31 on the rheological properties of Phosphate Buffer Saline (PBS) at various time intervals have been investigated. The viscosity of the PBS-AZ31 solution increased with the dissolution of both slurries and percolated clear solution. The only exception was day-7 of the percolated clear solution, where viscosity was decreased showing a reduction in viscosity at initial stages of dissolution. The frequency sweep showed the tendency of the PBS-AZ31 gelation up to 100 rad/s frequency.
Collapse
Affiliation(s)
- Usman Riaz
- School of Engineering and Technology, Central Michigan University, Mount Pleasant, MI 48859, USA
| | - Leela Rakesh
- Department of Mathematics, Center for Applied Mathematics & Polymer Fluid Dynamics, Central Michigan University, Mount Pleasant, MI 48859, USA
| | - Ishraq Shabib
- School of Engineering and Technology, Central Michigan University, Mount Pleasant, MI 48859, USA; Science of Advanced Materials, Central Michigan University, Mount Pleasant, MI 48859, USA
| | - Waseem Haider
- School of Engineering and Technology, Central Michigan University, Mount Pleasant, MI 48859, USA; Science of Advanced Materials, Central Michigan University, Mount Pleasant, MI 48859, USA.
| |
Collapse
|
2
|
Medvidovic-Grubisic M, Stambolija V, Kolenc D, Katancic J, Murselovic T, Plestina-Borjan I, Strbe S, Drmic D, Barisic I, Sindic A, Seiwerth S, Sikiric P. Hypermagnesemia disturbances in rats, NO-related: pentadecapeptide BPC 157 abrogates, L-NAME and L-arginine worsen. Inflammopharmacology 2017; 25:439-449. [PMID: 28210905 DOI: 10.1007/s10787-017-0323-6] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2016] [Accepted: 02/02/2017] [Indexed: 12/22/2022]
Abstract
AIM Stable gastric pentadecapeptide BPC 157, administered before a high-dose magnesium injection in rats, might be a useful peptide therapy against magnesium toxicity and the magnesium-induced effect on cell depolarization. Moreover, this might be an NO-system-related effect. Previously, BPC 157 counteracts paralysis, arrhythmias and hyperkalaemia, extreme muscle weakness; parasympathetic and neuromuscular blockade; injured muscle healing and interacts with the NOS-blocker and NOS-substrate effects. MAIN METHODS Assessment included magnesium sulfate (560 mg/kg intraperitoneally)-induced muscle weakness, muscle and brain lesions, hypermagnesemia, hyperkalaemia, increased serum enzyme values assessed in rats during and at the end of a 30-min period and medication (given intraperitoneally/kg at 15 min before magnesium) [BPC 157 (10 µg, 10 ng), L-NAME (5 mg), L-arginine (100 mg), alone and/or together]. In HEK293 cells, the increasing magnesium concentration from 1 to 5 mM could depolarize the cells at 1.75 ± 0.44 mV. KEY FINDINGS L-NAME + magnesium-rats and L-arginine + magnesium-rats exhibited worsened severe muscle weakness and lesions, brain lesions, hypermagnesemia and serum enzymes values, with emerging hyperkalaemia. However, L-NAME + L-arginine + magnesium-rats exhibited all control values and normokalaemia. BPC 157 abrogated hypermagnesemia and counteracted all of the magnesium-induced disturbances (including those aggravated by L-NAME or L-arginine). Thus, cell depolarization due to increasing magnesium concentration was inhibited in the presence of BPC 157 (1 µM) in vitro. SIGNIFICANCE BPC 157 likely counteracts the initial event leading to hypermagnesemia and the life-threatening actions after a magnesium overdose. In contrast, a worsened clinical course, higher hypermagnesemia, and emerging hyperkalaemia might cause both L-NAME and L-arginine to affect the same events adversely. These events were also opposed by BPC 157.
Collapse
Affiliation(s)
- Maria Medvidovic-Grubisic
- Department of Pharmacology, School of Medicine, University of Zagreb, Salata 11, P.O. Box 916, 10000, Zagreb, Croatia
| | - Vasilije Stambolija
- Department of Pharmacology, School of Medicine, University of Zagreb, Salata 11, P.O. Box 916, 10000, Zagreb, Croatia
| | - Danijela Kolenc
- Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - Jadranka Katancic
- Department of Pharmacology, School of Medicine, University of Zagreb, Salata 11, P.O. Box 916, 10000, Zagreb, Croatia
| | - Tamara Murselovic
- Department of Pharmacology, School of Medicine, University of Zagreb, Salata 11, P.O. Box 916, 10000, Zagreb, Croatia
| | - Ivna Plestina-Borjan
- Department of Pharmacology, School of Medicine, University of Zagreb, Salata 11, P.O. Box 916, 10000, Zagreb, Croatia
| | - Sanja Strbe
- Department of Pharmacology, School of Medicine, University of Zagreb, Salata 11, P.O. Box 916, 10000, Zagreb, Croatia
| | - Domagoj Drmic
- Department of Pharmacology, School of Medicine, University of Zagreb, Salata 11, P.O. Box 916, 10000, Zagreb, Croatia
| | - Ivan Barisic
- Department of Pharmacology, School of Medicine, University of Zagreb, Salata 11, P.O. Box 916, 10000, Zagreb, Croatia
| | - Aleksandra Sindic
- Department of Physiology and Immunology, School of Medicine, Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - Sven Seiwerth
- Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - Predrag Sikiric
- Department of Pharmacology, School of Medicine, University of Zagreb, Salata 11, P.O. Box 916, 10000, Zagreb, Croatia.
| |
Collapse
|